睿知中国疾病研究地图
候选清单0

正在招募胃癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

ClinicalTrials.gov 上登记的一项胃癌开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06341595,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Has histologically confirmed diagnosis of gastric or GEJ adenocarcinoma;

    入选标准第 3 条

  3. Thyroid function was normal, defined as thyroid stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled;

    入选标准第 19 条

    Unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) classification ≥ 2;

    排除标准第 23 条

  4. other malignant diseases other than gastric cancer diagnosed within 5 years before the first administration (excluding skin basal cell carcinoma, skin squamous epithelial carcinoma, and / or carcinoma in situ after radical resection);

    排除标准第 4 条

    Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, anti-PD L2 , anti-CD137,anti-CTLA-4 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137);

    排除标准第 6 条

    have received systemic treatment with Chinese patent drugs with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, except for local use to control ascites) within 2 weeks before the first administration;

    排除标准第 7 条

    have not fully recovered from the toxicity and / or complications caused by any intervention before starting treatment (i.e., ≤ grade 1 or reaching baseline, excluding fatigue or hair loss);

    排除标准第 13 条

  5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

    入选标准第 9 条

  6. The absolute neutrophil count (ANC) ≥ 1.5x109/l without granulocyte colony stimulating factor in the past 14 days.

    入选标准第 12 条

    Platelets ≥ 100 without blood transfusion in recent 14 days × 109/l.

    入选标准第 13 条

    Hemoglobin >9g/dl without blood transfusion or use of erythropoietin in recent 14 days;

    入选标准第 14 条

    Total bilirubin ≤ 1.5 × Upper limit of normal value (ULN);

    入选标准第 15 条

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were ≤ 2.5 × ULN (ALT or AST ≤ 5 allowed for subjects with liver metastasis × ULN);

    入选标准第 16 条

    Blood creatinine ≤ 1.5 × ULN and creatinine clearance (calculated by Cockcroft Gault formula) ≥ 60 ml/min;

    入选标准第 17 条

  7. Human Immunodeficiency Virus (HIV) infection (HIV antibody positive) (i.e. HIV 1/2 antibody positive);

    排除标准第 14 条

    HBV viral load was <1000 copies /ml (200 iu/ml) before the first dose, and subjects should receive anti HBV treatment throughout the study drug treatment period to avoid virus reactivation

    排除标准第 16 条

    For subjects with anti HBC (+), HBsAg (-), anti HBS (-) and HBV viral load (-), prophylactic anti HBV treatment is not required, but viral reactivation needs to be closely monitored

    排除标准第 17 条

    active HCV infected subjects (HCV antibody positive and HCV-RNA level higher than the lower limit of detection);

    排除标准第 18 条

  8. Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test at the timing of enrollment. Women of non-childbearing potential was defined as having a cessation of menses for one or more year or having surgical sterilization/Hysterectomy

    入选标准第 20 条

    Women who are pregnant or nursing.

    排除标准第 20 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06341595,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Able to provide informed consent and willing to sign an approved consent form;
  2. age ≥ 18 years old and ≤ 75 years old, male and female;
  3. Has histologically confirmed diagnosis of gastric or GEJ adenocarcinoma;
  4. patients with advanced gastric cancer who have para aortic lymph node metastasis at the initial treatment and whose primary tumor site can be treated with D2 radical operation;
  5. peritoneal exploration to exclude peritoneal metastasis, liver metastasis and other metastasis;
  6. CT or MRI, PET-CT and other examinations suggest that there is only one unresectable factor, namely, para aortic lymph node metastasis;
  7. has not receive previous anti-tumor treatment (radiotherapy, chemotherapy, targeted or immunotherapy, etc.);
  8. Has at least one measurable lesion as defined by RECIST 1.1 as determined by investigator assessment.
  9. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
  10. expected survival time >3 months;
  11. sufficient organ function, the subject needs to meet the following laboratory indicators:
  12. The absolute neutrophil count (ANC) ≥ 1.5x109/l without granulocyte colony stimulating factor in the past 14 days.
  13. Platelets ≥ 100 without blood transfusion in recent 14 days × 109/l.
  14. Hemoglobin >9g/dl without blood transfusion or use of erythropoietin in recent 14 days;
  15. Total bilirubin ≤ 1.5 × Upper limit of normal value (ULN);
  16. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were ≤ 2.5 × ULN (ALT or AST ≤ 5 allowed for subjects with liver metastasis × ULN);
  17. Blood creatinine ≤ 1.5 × ULN and creatinine clearance (calculated by Cockcroft Gault formula) ≥ 60 ml/min;
  18. Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN;
  19. Thyroid function was normal, defined as thyroid stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range can also be enrolled;
  20. Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test at the timing of enrollment. Women of non-childbearing potential was defined as having a cessation of menses for one or more year or having surgical sterilization/Hysterectomy
  21. Participants of childbearing potential must be willing to use an adequate method of contraception (method with failure rate less than 1% in a year)for the course of the study through 120 days after the last dose of study medication or through 180 days of last dose of chemotherapy.

排除标准:Exclusion Criteria:

  1. HER-2 positive status
  2. peritoneal or other organ metastasis;
  3. endoscopy shows signs of active bleeding, and history of gastrointestinal perforation and /or fistula within 6 months before enrollment.;
  4. other malignant diseases other than gastric cancer diagnosed within 5 years before the first administration (excluding skin basal cell carcinoma, skin squamous epithelial carcinoma, and / or carcinoma in situ after radical resection);
  5. Is currently participating in and receiving study therapy , or having been treated with another research drug or with an investigational medical devices within 4 weeks before the first administration;
  6. Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, anti-PD L2 , anti-CD137,anti-CTLA-4 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137);
  7. have received systemic treatment with Chinese patent drugs with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, except for local use to control ascites) within 2 weeks before the first administration;
  8. active autoimmune disease requiring systemic treatment (such as the use of disease modifying drugs, glucocorticoids or immunosuppressants) occurred within 2 years before the first administration. Alternative therapies (such as thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency, etc.) are not considered systemic treatments;
  9. being treated with systemic glucocorticoids (excluding nasal spray, inhalation or other local glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first dose of the study;
  10. Known history of allogeneic organ (except corneal transplantation) or allogeneic hemopoietic stem cell transplantation;
  11. Known allergy or hypersensitivity to the investigational drugs Sintilimab, Oxaliplatin, S-1 or excipients;
  12. there are many factors that affect oral drugs (such as inability to swallow, after gastrointestinal resection, chronic diarrhea and intestinal obstruction, cardiac and pyloric obstruction affecting eating and gastric emptying);
  13. have not fully recovered from the toxicity and / or complications caused by any intervention before starting treatment (i.e., ≤ grade 1 or reaching baseline, excluding fatigue or hair loss);
  14. Human Immunodeficiency Virus (HIV) infection (HIV antibody positive) (i.e. HIV 1/2 antibody positive);
  15. uncontrolled active hepatitis B (defined as HBsAg positive with HBV-DNA copy number greater than the upper limit of normal value in the laboratory of the research center);
  16. HBV viral load was <1000 copies /ml (200 iu/ml) before the first dose, and subjects should receive anti HBV treatment throughout the study drug treatment period to avoid virus reactivation
  17. For subjects with anti HBC (+), HBsAg (-), anti HBS (-) and HBV viral load (-), prophylactic anti HBV treatment is not required, but viral reactivation needs to be closely monitored
  18. active HCV infected subjects (HCV antibody positive and HCV-RNA level higher than the lower limit of detection);
  19. vaccinated with live vaccine within 30 days before the first administration (cycle 1, day 1);
  20. Women who are pregnant or nursing.
  21. there are any serious or uncontrollable systemic diseases, such as:
  22. The resting ECG has major abnormalities in rhythm, conduction or morphology, and the symptoms are serious and difficult to control, such as complete left bundle branch block, heart block above grade II, ventricular arrhythmia or atrial fibrillation;
  23. Unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) classification ≥ 2;
  24. Any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, occurred within 6 months before enrollment;
  25. Blood pressure control was not ideal (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg);
  26. There was a history of non infectious pneumonia requiring glucocorticoid treatment within 1 year before the first administration, or there was currently clinically active interstitial lung disease;
  27. Active pulmonary tuberculosis;
  28. The presence of active or uncontrolled infections requiring systemic treatment;
  29. There were clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction;
  30. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis;
  31. Poor control of diabetes (fasting blood glucose (FBG) > 10mmol/l);
  32. The urine routine showed that the urine protein was ≥ + +, and the 24-hour urine protein quantitation was confirmed to be > 1.0 G;
  33. Those who have mental disorders and cannot cooperate with treatment;
  34. Other acute or chronic diseases, mental illness, or abnormal laboratory test results that may lead to the following outcomes: increase the risk of participating in study or study drug administration, or interfere with the interpretation of the study results and considered by investigator as "NOT" eligible to participate in this study.

引自 ClinicalTrials.gov, NCT06341595, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06341595,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06341595